Magnetite-Gold nanohybrids as ideal all-in-one platforms for theranostics (original) (raw)
Related papers
Size-selected Fe3O4–Au hybrid nanoparticles for improved magnetism-based theranostics
Beilstein Journal of Nanotechnology
Size-selected Fe3O4–Au hybrid nanoparticles with diameters of 6–44 nm (Fe3O4) and 3–11 nm (Au) were prepared by high temperature, wet chemical synthesis. High-quality Fe3O4 nanocrystals with bulk-like magnetic behavior were obtained as confirmed by the presence of the Verwey transition. The 25 nm diameter Fe3O4–Au hybrid nanomaterial sample (in aqueous and agarose phantom systems) showed the best characteristics for application as contrast agents in magnetic resonance imaging and for local heating using magnetic particle hyperthermia. Due to the octahedral shape and the large saturation magnetization of the magnetite particles, we obtained an extraordinarily high r 2-relaxivity of 495 mM−1·s−1 along with a specific loss power of 617 W·gFe −1 and 327 W·gFe −1 for hyperthermia in aqueous and agarose systems, respectively. The functional in vitro hyperthermia test for the 4T1 mouse breast cancer cell line demonstrated 80% and 100% cell death for immediate exposure and after precultivat...
Nanomaterials
Significant attention is paid to the design of magnetoplasmonic nanohybrids, which exploit synergistic properties for biomedical applications. Here, a facile method was employed to prepare plasmonic magnetic Au-MnO heterostructured hybrid nanoparticles for imaging-guided photothermal therapy of cancers in vitro, with the view to reducing the serious drawbacks of chemotherapy and gadolinium-based contrast agents. The biocompatibility of the prepared Au-MnO nanocomposites was further enhanced by Food and Drug Administration (FDA)-approved triblock copolymers Pluronic® F-127 and chitosan oligosaccharide (COS), with complementary support to enhance the absorption in the near-infrared (NIR) region. In addition, synthesized COS-PF127@Au-MnO nanocomposites exhibited promising contrast enhancement in T1 MR imaging with a good r1 relaxivity value (1.2 mM−1 s−1), demonstrating a capable substitute to Gd-based toxic contrast agents. In addition, prepared COS-PF127@Au-MnO hybrid nanoparticles (...
Colloids and Surfaces B: Biointerfaces, 2015
Small hybrid nanoparticles composed of highly biocompatible Ag 2 S quantum dots (QD) emitting in the near-infrared region and superparamagnetic iron oxide (SPION) are produced in a simple extraction method utilizing ligand exchange mechanism. Hybrid nanoparticles luminesce at the same wavelength as the parent QD, therefore an array of hybrid nanoparticles with emission between 840 and 912 nm were easily produced. Such hybrid structures have (1) strong luminescence in the medical imaging window eliminating the autofluoresence of cells as effective optical probes, (2) strong magnetic response for magnetic targeting and (3) good cyto/hemocompatibility. An interesting size dependent cytotoxicity behavior was observed in HeLa and NIH/3T3 cell lines: smallest particles are internalized significantly more by both of the cell lines, yet showed almost no significant cytotoxicity in HeLa between 10 and 25 g/mL Ag concentration but were most toxic in NIH/3T3 cells. Cell internalization and hence the cytotoxicity enhanced when cells were incubated with the hybrid nanoparticles under magnetic field, especially with the hybrid nanoparticles containing larger amounts of SPION in the hybrid composition. These results prove them as effective optical imaging agents and magnetic delivery vehicles. Combined with the known advantages of SPIONs as a contrast agent in MRI, these particles are a step forward for new theranostics for multimode imaging and magnetic targeting.
Journal of Cancer Research and Clinical Oncology, 2019
Recent efforts in the area of photothermal therapy (PTT) follow two important aims: (i) selective targeting of plasmonic nanoparticles to the tumor and (ii) real-time guidance of PTT operation through employing multimodal imaging modalities. In the present study, we utilized a multifunctional theranostic nanoplatform constructed from iron (III) oxide-gold (Fe 2 O 3 @Au) core-shell nanoparticles to fulfill these aims. The Au shell exhibits surface plasmon resonance, a property that is exploited to realize PTT. The magnetic core enables Fe 2 O 3 @Au to be employed as a magnetic resonance imaging (MRI) contrast agent. Furthermore, the magnetic core has the potential to establish a magnetic drug targeting strategy through which Fe 2 O 3 @Au can be directed to the tumor site by means of magnetic field. To test these potentials, Balb/c mice bearing CT26 colorectal tumor model were intravenously injected with Fe 2 O 3 @Au. Immediately after injection, a magnet was placed on the tumor site for 3 h to concentrate nanoparticles, followed by the near infrared (NIR) laser irradiation. MRI study confirmed the accumulation of nanoparticles within the tumor due to T2 enhancement capability of Fe 2 O 3 @Au. The in vivo thermometry results demonstrated that the tumors in magnetic targeting group had a significantly higher temperature elevation rate upon NIR irradiation than non-targeted group (~ 12 °C vs. 8.5 °C). The in vivo antitumor assessment revealed that systemic injection of Fe 2 O 3 @Au in combination with magnetic targeting and NIR irradiation resulted in complete remission of tumor growth. Therefore, Fe 2 O 3 @Au can establish a targeted PTT strategy for efficient eradication of tumor cells under the guidance of MRI.
Nanomedicine (London, England), 2017
Recent advances in the development of magnetic nanoparticles (MNPs) have shown promise in the development of new personalized therapeutic approaches for clinical management of cancer patients. The unique physicochemical properties of MNPs endow them with novel multifunctional capabilities for imaging, drug delivery and therapy, which are referred to as theranostics. To facilitate the translation of those theranostic MNPs into clinical applications, extensive efforts have been made on designing and improving biocompatibility, stability, safety, drug-loading ability, targeted delivery, imaging signal and thermal- or photodynamic response. In this review, we provide an overview of the physicochemical properties, toxicity and theranostic applications of MNPs with a focus on magnetic iron oxide nanoparticles.
Magnetic Nanoparticles for Tumor Imaging and Therapy: A So-Called Theranostic System
Pharmaceutical Research, 2013
In this review, we discussed the establishment of a so-called "theranostic" system by instituting the basic principles including the use of: [1] magnetic iron oxide nanoparticles (MION)-based drug carrier; [2] intra-arterial (I.A.) magnetic targeting; [3] macromolecular drugs with unmatched therapeutic potency and a repetitive reaction mechanism; [4] cell-penetrating peptide-mediated cellular drug uptake; and [5] heparin/protamine-regulated prodrug protection and tumor-specific drug re-activation into one single drug delivery system to overcome all possible obstacles, thereby achieving a potentially non-invasive, magnetic resonance imaging-guided, clinically enabled yet minimally toxic brain tumor drug therapy. By applying a topography-optimized I.A. magnetic targeting to dodge rapid organ clearance of the carrier during its first passage into the circulation, tumor capture of MION was enriched by >350 folds over that by conventional passive enhanced permeability and retention targeting. By adopting the prodrug strategy, we observed by far the first experimental success in a rat model of delivering micro-gram quantity of the large β-galactosidase model protein selectively into a brain tumor but not to the ipsi-or contra-lateral normal brain regions. With the therapeutic regimens of most toxin/siRNA drugs to fully (>99.9%) eradicate a tumor being in the nano-molar range, the prospects of reaching this threshold become practically accomplishable.
An original route to stabilize and functionalize magnetite nanoparticles for theranosis applications
Journal of Magnetism and Magnetic Materials, 2011
A versatile method for the introduction of cyano groups onto the surface of iron oxide nanoparticles has been developed. This protocol is based on the hydrolysis and the condensation of cyanoethyltrimethoxysilane (CES) on the magnetite surface. The optimal concentration of silane coupling agent was determined ([Fe]/[CN] ratio ¼ 0.4) in order to obtain an appropriate surface density of activating groups on the nanoparticles. The size distribution of the particles was also optimized by a magnetic size sorting procedure. An adequate surface with cyano groups could facilitates their use in biomedical applications by improving the cellular labeling and the cell targeting.
Gd-Doped Superparamagnetic Magnetite Nanoparticles for Potential Cancer Theranostics
Nanostructured Materials - Fabrication to Applications, 2017
Nanotechnology has facilitated the applications of a class of nanomaterials called superparamagnetic iron oxide nanoparticles (SPIONs) in cancer theranostics. This is a new discipline in biomedicine that combines therapy and diagnosis in one platform. The multifunctional SPIONs, which are capable of detecting, visualizing, and destroying the neoplastic cells with fewer side effects than the conventional therapies, are reviewed in this chapter for theranostic applications. The chapter summarizes the design parameters such as size, shape, coating, and target ligand functionalization of SPIONs, which enhance their ability to diagnose and treat cancer. The review discusses the methods of synthesizing SPIONs, their structural, morphological, and magnetic properties that are important for theranostics. The applications of SPIONs for drug delivery, magnetic resonance imaging, and magnetic hyperthermia therapy (MHT) are included. The results of our recent MHT study on Gd-doped SPION as a possible theranostic agent are highlighted. We have also discussed the challenges and outlook on the future research for theranostics in clinical settings.